Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

AOU data comprised electronic health records (EHRs) of 18,746 adult T2D patients (57% female) who initiated GLP‑1 RA, SGLT2i, or DPP4i therapies on or after January 2018.

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

Findings from two groundbreaking studies highlight potential pharmacological and biosensor solutions for muscle mass preservation in patients undergoing obesity treatment therapy. Results from the ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

A matched cohort of 139,002 patients was created, with 46,334 patients exposed to GLP-1 RAs and 92,668 unexposed patients.

LA-GLP1 RA Effects on the Risk of Medullary Thyroid Cancer GLP-1 receptors are present in several tissues including the pancreas, intestine, stomach, nervous system and others.

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity.